Jeremy Tay

Angelo, Gordon & Co. LP (Angelo Gordon) is a SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Michael L. Gordon in 1988. They were acquired by TPG, Inc. (NASDAQ: TPG) in 2023. Angelo Gordon invests on behalf of pension funds, corporations, endowments, foundations, sovereign wealth funds and individuals.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Part of Match Group, Inc., SK Holdings, Inc. is a company based in New York, NY.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

Portfolio Advisors LLC (Portfolio Advisors) is a private equity firm founded in 1994. The firm is headquartered in Darien, Connecticut with additional offices in Dallas, London, Zurich, Hong Kong and Singapore.

New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California.

FIG LLC (Private Equity) (FIG) is a private equity firm subsidiary of FIG LLC founded in 1998 by Wesley Edens, Randal Nardone, and Robert Kauffman. The firm is headquartered in New York.

New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group.

Crestline Investors, Inc (Crestline Investors) is a private equity firm founded in 1997 by Douglas Bratton. The firm is headquartered in Fort Worth, Texas.

Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA.

The Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. Leveraging the rich history of Japanese technological prowess, the INCJ aims to provide financial, technological and management support in order to promote the creation of next-generation businesses through 'open innovation,' or the flow of technology and expertise beyond the boundaries of existing organizational structures. The INCJ will draw on funding as well as management and technological expertise from the public and private sectors. The INCJ is actively reviewing various investment opportunities in areas of environment and energy, electronics and IT, bio-tech, and infrastructure such as water supply, railway service, and nuclear power supply. Each investment will be thoroughly vetted to ensure it meets the exacting standards of the INCJ's Innovation Network Committee, which will make the final investment decisions. The INCJ is capitalized at 92 billion yen, with the Japanese government injecting 82 billion yen and 19 private corporations (refer to details in Appendix below) providing a further 10 billion yen. The government will also provide guarantees up to a total of 800 billion yen for INCJ investments, giving it an investment capability of approximately 900 billion yen (US$10 billion). The INCJ will be established for a period of 15 years.

Themes Investment Management Ltd is a private equity firm founded in 2009. The firm is headquartered in Hong Kong.

Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China.

Wisdoms Auto Parts (Changzhou) Co., Ltd. operates as a holding company that manufactures automobile engines and parts. Its business activities include the manufacturing of general machinery parts, vehicle electrical machinery parts, mould and parts, clamp and its components, as well as the provision of related manufacturing technical consulting services. The company was founded on April 10, 2008 and is headquartered in Changzhou, China.

Fosun Group Finance Corp., Ltd. provides financial products and services. Its services include financial consulting, guarantee and payment services for member units, insurance agency, entrusted loans and entrusted investments, bills acceptance and discounting, factoring, interbank lending, and fixed income investments. The company was founded in June 2011 and is headquartered in Shanghai, China.

Korea Evaluation Institute of Industrial Technology operates as a research institute to develop technology for domestic industries. The company is based in Daegu, South Korea. The South Korean company is ultimately controlled by the Government of South Korea.

I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China.

Lunia Capital LP is an independent hedge fund management firm headquartered in Dallas, Texas. The firm was founded by Vikas Lunia in 2016. Lunia Capital provides investment advisory services to one or more private investment funds and/or separately managed accounts. Investors in the fund and/or owners of managed accounts may include, but are not limited to, high net worth individuals, family offices, fund-of-hedge funds, endowments, foundations, trusts, charitable organizations, pension plans, and corporate or business entities.

I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China.

Fermenstation Co., Ltd. is a company based in Tokyo, Japan that specializes in OEM and ODM of organic cosmetics and sustainable products. The Japanese company caters to the demand for clean beauty, vegan, and organic certified products. The company offers a complete service from proposing raw materials tailored to the customer's needs to developing original products with a story. Fermenstation Co. was founded in 2009 by Hayato Watanabe and Rina Sakai.

PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan.

Part of State of Texas, Texas Permanent School Fund invests for the benefit of public schools. The company is based in Austin, TX. The company was created in 1845 as a perpetual fund to support the state's public schools and has since grown to comprise over $51 billion. The company's Bond Guarantee Program guarantees bonds issued by independent and charter school districts, enhancing their credit rating. The program is designed for school districts with credit ratings lower than AAA. PSF makes biennial distributions into the Available School Fund, a fund established for the support and maintenance of public K-12 and charter schools.

AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao.

InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then.

C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York..

Portola Capital Partners is a private equity firm founded in 1992. The firm is headquartered in Silicon Valley, California.